4.
患者经EGFR-TKIs治疗的PFS
PFS in patients treated with EGFR-TKIs
| Mean (95%CI) (months) | χ2 | Univariate analysis P |
|
| Gender | 2.388 | 0.12 | |
| Male | 16.3 (11.5-21.2) | ||
| Female | 13.9 (8.8-19.0) | ||
| Age (year) | 0.376 | 0.54 | |
| > 60 | 12.8 (8.5-17.0) | ||
| < 60 | 16.8 (10.5-23.3) | ||
| Stage | 0.011 | 0.92 | |
| Ⅰa-Ⅲa | 16.1 (0.0-32.3) | ||
| Ⅲb-Ⅳ | 16.3 (12.0-20.6) | ||
| Smoking history | 2.642 | 0.10 | |
| No | 15.4 (10.5-20.2) | ||
| Yes | 14.0 (9.7-18.3) | ||
| EGFR mutations | 7.876 | 0.049 | |
| 18 G719X | 15.8 (9.5-22.2) | ||
| 21L861Q | 8.0 (5.1-11.0) | ||
| Other single mutations | 4.9 (1.4-8.4) | ||
| Complex mutations | 23.1 (15.8-30.4) | ||
| Lines of treatment | 0.527 | 0.77 | |
| 1st line | 14.8 (9.6-20.0) | ||
| 2nd line | 11.7 (8.4-15.1) | ||
| 3rd line | 24.4 (24.4-24.4) | ||
| EGFR-TKIs | 3.396 | 0.334 | |
| Gefitinib | 11.5 (7.3-15.7) | ||
| Icotinib | 20.7 (13.7-27.7) | ||
| Erlotinib | 24.4 |